You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,731,082

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,731,082 protect, and when does it expire?

Patent 9,731,082 protects DILAUDID and DILAUDID-HP and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 9,731,082

Patent landscape, scope, and claims:

Title:	Drug container
Abstract:	The present invention relates to an assembly (101) comprising: an injection device (1) comprising a container (2) for a product, said container comprising a distal tip (3), an adaptor (5) comprising a ring (6) mounted onto said distal tip (3), characterized in that said assembly (101) further comprises a heat-shrinkable film (9) covering part (2a) of said container (2) and part (5a) of said adaptor (5), said film (9) maintaining said adaptor (5) blocked in rotation and in translation with respect to said container (2) when said film (9) is in its heat-shrunk condition. The invention further relates to a method for manufacturing such an assembly.
Inventor(s):	Vernizeau; Michel (Valence, FR), Foucher; Cedric (Grenoble, FR), Lefebvre; Lionel (Varois et Chaignot, FR)
Assignee:	Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:	13/132,285
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,731,082
Patent Claim Types: see list of patent claims	Use; Device; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,731,082

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-006	Jan 16, 2020	AP	RX	Yes	Yes	9,731,082	⤷ Subscribe	Y				⤷ Subscribe
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-007	Feb 10, 2017	AP	RX	Yes	Yes	9,731,082	⤷ Subscribe	Y				⤷ Subscribe
Fresenius Kabi Usa	DILAUDID	hydromorphone hydrochloride	INJECTABLE;INJECTION	019034-003	Apr 30, 2009	AP	RX	Yes	Yes	9,731,082	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,731,082

PCT Information
PCT Filed	December 02, 2008	PCT Application Number:	PCT/IB2008/003736
PCT Publication Date:	June 10, 2010	PCT Publication Number:	WO2010/064074

International Family Members for US Patent 9,731,082

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	2376147	⤷ Subscribe
European Patent Office	2376147	⤷ Subscribe
Spain	2693123	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.